De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy
Viruses · 2024
DOI: 10.3390/v16040536 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Wendell G Yarbrough und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology/Head and Neck Surgery, UNC School of Medicine, Chapel Hill, NC 27599, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Biomarkers, Tumor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, NCI NIH HHS, Dissecting NF-kB Pathway in HPV-Associated Head and Neck Cancer.
Abstract (Originalsprache)
Human papillomavirus-associated (HPV+) head and neck squamous cell carcinoma (HNSCC) is the most common HPV-associated cancer in the United States, with a rapid increase in incidence over the last two decades. The burden of HPV+ HNSCC is likely to continue to rise, and given the long latency between infection and the development of HPV+ HNSCC, it is estimated that the effect of the HPV vaccine will not be reflected in HNSCC prevalence until 2060. Efforts have begun to decrease morbidity of standard therapies for this disease, and its improved characterization is being leveraged to identify and target molecular vulnerabilities. Companion biomarkers for new therapies will identify responsive tumors. A more basic understanding of two mechanisms of HPV carcinogenesis in the head and neck has identified subtypes of HPV+ HNSCC that correlate with different carcinogenic programs and that identify tumors with good or poor prognosis. Current development of biomarkers that reliably identify these two subtypes, as well as biomarkers that can detect recurrent disease at an earlier time, will have immediate clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology/Head and Neck Surgery, UNC School of Medicine, Chapel Hill, NC 27599, USA.
- Department of Pathology and Lab Medicine, UNC School of Medicine, Chapel Hill, NC 27599, USA.
- Lineberger Comprehensive Cancer Center, UNC School of Medicine, Chapel Hill, NC 27599, USA.
- Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA.
- Yale Cancer Center, Yale School of Medicine, New Haven, CT 06510, USA.
ORCID-Profile: Wendell G Yarbrough, Natalia Issaeva
Förderung
- NIDCR NIH HHS
- NCI NIH HHS
- Dissecting NF-kB Pathway in HPV-Associated Head and Neck Cancer
- Exploring Mechanisms of Therapeutic Demethylation Effects in HPV-Associated Head and Neck Cancer
- Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers for Diagnosis and Treatment of HPV-Associated OPSCC
- Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head & Neck Cancer
Zitieren
APA
Yarbrough, W. G., Schrank, T. P., Burtness, B. A., & Issaeva, N. (2024). De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy. Viruses. https://doi.org/10.3390/v16040536
Vancouver
Yarbrough WG, Schrank TP, Burtness BA, Issaeva N. De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy. Viruses. 2024. doi:10.3390/v16040536
BibTeX
@article{Yarbrough2024,
author = {Yarbrough, Wendell G and Schrank, Travis P and Burtness, Barbara A and Issaeva, Natalia},
title = {De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16040536}
}
EUVIMED